Lai-Ying Zhang

Dr. Lai-Ying Zhang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
LZLai-Ying Zhang
Lai-Ying Zhang
LZLaurie Zhong
Laurie Zhong
MDMichael David
Michael David
ACAnders Cervin
Anders Cervin

Verified
Journal Article
Open access
PDF file
PGPenny Groves
Penny Groves
LHLevi Hockey
Levi Hockey
BOBrendan O'Sullivan
Brendan O'Sullivan
LZLai-Ying Zhang
Lai-Ying Zhang
ZXZherui Xiong
Zherui Xiong
Simon H ApteSimon H Apte
Simon H Apte
Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.

8 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PGPenny Groves
Penny Groves
LHLevi Hockey
Levi Hockey
BOBrendan O'Sullivan
Brendan O'Sullivan
LZLai-Ying Zhang
Lai-Ying Zhang
ZXZherui Xiong
Zherui Xiong
Simon H ApteSimon H Apte
Simon H Apte
Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.

17 June 2022 in Australasian Psychiatry
Verified
Journal Article
Closed access
LZLai-Ying Zhang
Lai-Ying Zhang
JAJames Anderson
James Anderson
NHNiall Higgins
Niall Higgins
JRJan Robinson
Jan Robinson
SFSonia Francey
Sonia Francey
GTGeorge Tay
George Tay
Objective: Patients with serious mental illness (SMI) are at increased risk of obstructive sleep apnoea (OSA). Despite this, OSA is frequently under-recognised in the psychiatric population. This study describes the results of OSA screening in SMI patients. Method: Patients with SMI attending a metropolitan mental health clinic were screened for OSA using the OSA50, STOP-BANG Questionnaire (SBQ), Epworth Sleep Score (ESS) and the Pittsburgh Sleep Quality Index (PSQI). They were then offered diagnostic sleep testing via ResMed ApneaLink TM and polysomnography. Results: Of the 65 patients recruited, 65% had a primary diagnosis of schizophrenia or schizoaffective disorder, 85% were on antipsychotic medications and the majority were obese. Approximately 50% of patients reported poor sleep quality via the PSQI, in contrast to 12% with elevated daytime sleepiness via the ESS. 46% of our cohort were at risk of OSA due to an elevated OSA50 or SBQ. Of the five patients who agreed to proceed to diagnostic sleep testing, three were diagnosed with OSA. Conclusion: A high proportion of patients with psychiatric illness are at risk of sleep-disordered breathing. Sleep dissatisfaction is high. The low uptake of sleep investigation requires improved patient engagement to improve OSA diagnosis in this high-risk group.

29 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLai-Ying Zhang
Lai-Ying Zhang
PAPeter C. Allen
Peter C. Allen
VLViviana P. Lutzky
Viviana P. Lutzky
Simon H ApteSimon H Apte
Simon H Apte
PGPenny L. Groves
Penny L. Groves
BOBrendan J. O’SUllivan
Brendan J. O’SUllivan
Rationale: Interstitial lung diseases (ILDs) encompass a diverse range of fibrotic conditions and contribute to significant respiratory morbidity and mortality. Assessment of the cellular composition of bronchoalveolar lavage (BAL) fluid is an important diagnostic test in people presenting with ILD, but BAL cellularity remains relatively uncharacterized at single-cell resolution. Objective: To characterize immune cell populations in BAL across different ILDs and investigate the impact of shortened peripheral blood leukocyte telomere length on BAL immune profiles. Methods: Single-cell RNA sequencing and downstream analysis were performed on BAL samples from 24 male patients with various ILDs, including idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, and silicosis. Both normal-telomere and short-telomere patients were included. Additionally, we integrated our findings with IPF genome-wide association study (GWAS) data. Results: We identified sixteen distinct cell populations in BAL with notable differences across ILD subtypes. Analysis revealed six monocyte-like macrophage (MLM) subclusters following divergent trajectories: inflammatory CXCL10 hi MLMs predominated in hypersensitivity pneumonitis, while pro-fibrotic SPP1 hi MLMs were significantly expanded in IPF. Short-telomere patients showed a trend toward increased proportion of pro-fibrotic SPP1 hi MLMs, with enhanced expression of fibrotic genes compared to patients with normal telomere length. Integration with genomic data confirmed that SPP1 hi and CCL2 hi MLM subclusters harbour cells with the highest IPF disease relevance scores. Conclusion: BAL-derived transcriptomics reveals distinct myeloid subpopulations across ILD subtypes, with specific populations associated with disease pathogenesis. These findings provide insight into ILD pathogenesis, motivate the development of more sophisticated diagnostic tests using BAL sampling, and highlight specific myeloid subpopulations as potential therapeutic targets.